The company's diagnostic tests may obtain better coverage from the Centers for Medicare & Medicaid Services.
GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 16.67% and 1.16%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Natera (NTRA) delivered earnings and revenue surprises of -4.24% and 6.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Progyny (PGNY) delivered earnings and revenue surprises of 125% and 5.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -13.33% and 4.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for first quarter ended March 31,...
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -7.69% and 10.23%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the fourth quarter and year ended...
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will participate...
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for the fourth quarter and year ended...